Ítem
Acceso Abierto

Plasmodium vivax Pv12 B-cell epitopes and HLA-DRβ1*-dependent T-cell epitopes in vitro antigenicity

Mostrar el registro sencillo de la publicación
dc.creatorYepes-Pérez, Yoelis
dc.creatorLópez, Carolina
dc.creatorFernando Suárez, Carlos
dc.creatorPatarroyo, Manuel A.
dc.creator.googleYepes-Pérez, Yoelisspa
dc.creator.googleLópez, Carolinaspa
dc.creator.googleFernando Suárez, Carlosspa
dc.creator.googlePatarroyo, Manuel Alfonsospa
dc.date.accessioned2019-02-15T14:34:38Z
dc.date.available2019-02-15T14:34:38Z
dc.date.created2018
dc.date.issued2018-09-10
dc.description.abstractMalaria is an infectious disease caused by parasites from the genus Plasmodium (P. falciparum and P. vivax are responsible for 90% of all clinical cases); it is widely distributed throughout the world’s tropical and subtropical regions. The P. vivax Pv12 protein is involved in invasion, is expressed on merozoite surface and has been recognised by antibodies from individuals exposed to the disease. In this study, B- and T-cell epitopes from Pv12 were predicted and characterised to advance in the design of a peptide-based vaccine against malaria. For evaluating the humoral response of individuals exposed to natural P. vivax infection from two endemic areas in Colombia, BepiPred-1.0 software was used for selecting B-cell epitopes. B-cell epitope 39038 displayed the greatest recognition by naturally-acquired antibodies and induced an IgG2/IgG4 response. NetMHCIIpan-3.1 prediction software was used for selecting peptides having high affinity binding for HLA-DRβ1* allele lineages and this was confirmed by in-vitro binding assays. T-epitopes 39113 and 39117 triggered a memory T-cell response (Stimulation Index2) and significant cytokine production. Combining in-silico, in-vitro and functional assays, two Pv12 protein regions (containing peptides 39038, 39040, 39113 and 39117) have thus been characterised as promising vaccine candidates against P. vivax malaria. © 2018 Yepes-Pérez et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0203715
dc.identifier.issn1932-6203
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/19081
dc.language.isoengspa
dc.relation.citationTitlePLoS ONE
dc.relation.citationVolumeVol. 13
dc.relation.ispartofPLoS ONE, ISSN:1932-6203, Vol. 13 (2018)spa
dc.relation.urihttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0203715&type=printablespa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.bibliographicCitation(2016) World Malaria Report 2015, p. 32. , WHO World Health Organizationspa
dc.source.instnameinstname:Universidad del Rosario
dc.source.reponamereponame:Repositorio Institucional EdocUR
dc.subject.ddcEnfermedadesspa
dc.subject.keywordAdultspa
dc.subject.keywordPlasmodium Vivax Malariaspa
dc.subject.keywordFemalespa
dc.subject.keywordMiddle Agedspa
dc.subject.keywordMononuclear Celleng
dc.subject.keywordMaleeng
dc.subject.keywordPeripheral Bloodeng
dc.subject.keywordMemory T Lymphocyteeng
dc.subject.keywordNonhumaneng
dc.subject.keywordLymphocyte Proliferationeng
dc.subject.keywordDrug Synthesiseng
dc.subject.keywordDrug Efficacyeng
dc.subject.keywordDrug Screeningeng
dc.subject.keywordClinical Articleeng
dc.subject.keywordClinical Assessmenteng
dc.subject.keywordBioinformaticseng
dc.subject.keywordCellular Immunityeng
dc.subject.keywordBinding Assayeng
dc.subject.keywordBinding Affinityeng
dc.subject.keywordAntigen Bindingeng
dc.subject.keywordAntigen Recognitioneng
dc.subject.keywordAntibody Responseeng
dc.subject.keywordDna Structureeng
dc.subject.keywordControlled Studyeng
dc.subject.keywordUnclassified Drugeng
dc.subject.keywordCytokine Productioneng
dc.subject.keywordAlleleeng
dc.subject.keywordProteineng
dc.subject.keywordPlasmodium Vivax 12eng
dc.subject.keywordDrug Antigenicityeng
dc.subject.keywordParasite Antigeneng
dc.subject.keywordIn Vitro Studyeng
dc.subject.keywordImmunoglobulin G2eng
dc.subject.keywordIc50eng
dc.subject.keywordImmunoglobulin G4eng
dc.subject.keywordHumoral Immunityeng
dc.subject.keywordHla Drb1 Antigeneng
dc.subject.keywordHla Dr Antigeneng
dc.subject.keywordDrug Designeng
dc.subject.keywordEpitopeeng
dc.subject.keywordHumaneng
dc.subject.keywordImmunosorbent Assayeng
dc.subject.keywordEnzyme Linkedeng
dc.subject.lembMalariaspa
dc.subject.lembPlasmodiumspa
dc.titlePlasmodium vivax Pv12 B-cell epitopes and HLA-DRβ1*-dependent T-cell epitopes in vitro antigenicityspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
18.pdf
Tamaño:
4.94 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos